Mechanistic description
Cancer/cystatin-C-mediated amyloid reduction decreases amyloid-nucleated tau pathology through reduced BACE1 activity and GSK3β activation. This hypothesis is almost certainly true but uninformative—it re-explains known downstream biology rather than identifying a novel mechanism. Should be demoted from ‘mechanism’ to ‘expected downstream consequence of amyloid lowering.’
Mechanism / pathway
- BACE1/GSK3β
- neurodegeneration
Evidence for (7)
Chronic peripheral inflammation elevates BACE1 and increases Aβ production
Amyloid plaque reduction via BACE inhibitors reduces tau PET signal in humans
Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged β-amyloid nanoscavenger for Alzheimer's disease therapy.
BACE1 and SCD1 are associated with neurodegeneration.
Combination strategy employing BACE1 inhibitor and memantine to boost cognitive benefits in Alzheimer's disease therapy.
From BACE1 inhibitor to multifunctionality of tryptoline and tryptamine triazole derivatives for Alzheimer's disease.
Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-κB/BACE1 Signaling Pathways.
Evidence against (2)
BACE1 inhibitors failed clinically despite amyloid reduction
Circular reasoning: reducing amyloid reduces tau is expected, not novel
Evidence matrix
Supporting
- Chronic peripheral inflammation elevates BACE1 and increases Aβ production PMID:29227873
- Amyloid plaque reduction via BACE inhibitors reduces tau PET signal in humans PMID:NA
- Nose-to-brain delivery of targeted lipid nanoparticles as two-pronged β-amyloid nanoscavenger for Alzheimer's disease therapy. PMID:40654363 · 2025 · Acta Pharm Sin B
- BACE1 and SCD1 are associated with neurodegeneration. PMID:37744400 · 2023 · Front Aging Neurosci
- Combination strategy employing BACE1 inhibitor and memantine to boost cognitive benefits in Alzheimer's disease therapy. PMID:38197930 · 2024 · Psychopharmacology (Berl)
- From BACE1 inhibitor to multifunctionality of tryptoline and tryptamine triazole derivatives for Alzheimer's disease. PMID:22781443 · 2012 · Molecules
- Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-κB/BACE1 Signaling Pathways. PMID:27977755 · 2016 · PLoS One
Contradicting
- BACE1 inhibitors failed clinically despite amyloid reduction PMID:NA
- Circular reasoning: reducing amyloid reduces tau is expected, not novel PMID:NA
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Synergistic reduction of amyloid-tau interaction through secondary effects. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-cf07e38ecd
@misc{scidex_hypothesis_hcf07e38,
title = {Synergistic reduction of amyloid-tau interaction through secondary effects},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-cf07e38ecd},
note = {SciDEX artifact hypothesis:h-cf07e38ecd}
}